ALPRE Stock Overview
Predilife S.A. develops and sells medical techniques and mathematical models.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Predilife S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.10 |
| 52 Week High | €6.80 |
| 52 Week Low | €3.60 |
| Beta | 0.25 |
| 1 Month Change | -5.53% |
| 3 Month Change | -24.07% |
| 1 Year Change | -29.91% |
| 3 Year Change | -43.84% |
| 5 Year Change | -50.30% |
| Change since IPO | -55.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALPRE | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -8.9% | -1.4% | -0.1% |
| 1Y | -29.9% | -13.0% | 1.3% |
Return vs Industry: ALPRE underperformed the French Biotechs industry which returned -13% over the past year.
Return vs Market: ALPRE underperformed the French Market which returned 1.3% over the past year.
Price Volatility
| ALPRE volatility | |
|---|---|
| ALPRE Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.5% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALPRE's share price has been volatile over the past 3 months.
Volatility Over Time: ALPRE's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 20 | Stephane Ragusa | www.predilife.com |
Predilife S.A. develops and sells medical techniques and mathematical models. The company provides prevention and breast check-up tests. Its products include MammoRisk, a test for predicting the development of breast cancer based on the patient’s individual risk; and DenSeeMammo, a breast density measurement software, as well as a medical device for the prediction of prostate cancer risk.
Predilife S.A. Fundamentals Summary
| ALPRE fundamental statistics | |
|---|---|
| Market cap | €15.17m |
| Earnings (TTM) | -€3.92m |
| Revenue (TTM) | €311.95k |
48.6x
P/S Ratio-3.9x
P/E RatioIs ALPRE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALPRE income statement (TTM) | |
|---|---|
| Revenue | €311.95k |
| Cost of Revenue | €970.92k |
| Gross Profit | -€658.97k |
| Other Expenses | €3.26m |
| Earnings | -€3.92m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.06 |
| Gross Margin | -211.24% |
| Net Profit Margin | -1,257.55% |
| Debt/Equity Ratio | -275.6% |
How did ALPRE perform over the long term?
See historical performance and comparison